Icovamenib

2 papers5 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab

Animals2

Outcomes

Body weight

downin rats1

1 study

Icovamenib decreases body weight in rats.
“In the ZDF rat, icovamenib in combination with sem enhanced body weight reduction through selectively promoting fat loss vs. sem alone.”
Animalswith semaglutide vs semaglutide alone in Zucker diabetic fatty rats
Icovamenib Rescues Human Myotube Atrophy Ex Vivo and Displays Complete Lean Mass Preservation in a Type 2 Diabetes Rat Model
ADA Scientific Sessions 2025 abstract13 Jun 2025

Lean mass fraction

upin rats1

1 study

Icovamenib increases lean mass fraction in rats (+12% from baseline (p=0.01)).
“Notably, combination-treated rats displayed a +12% change from baseline in the lean mass fraction (p=0.01), surpassing sem alone.”
Animalswith semaglutide in Zucker diabetic fatty rats
Icovamenib Rescues Human Myotube Atrophy Ex Vivo and Displays Complete Lean Mass Preservation in a Type 2 Diabetes Rat Model
ADA Scientific Sessions 2025 abstract13 Jun 2025

Myotube width

upin human cells1

1 study

Icovamenib increases myotube width in human cells.
“Dex decreased myotube width, which was rescued by icovamenib.”
Cellsdexamethasone-induced atrophymyotubes16 days
Icovamenib Rescues Human Myotube Atrophy Ex Vivo and Displays Complete Lean Mass Preservation in a Type 2 Diabetes Rat Model
ADA Scientific Sessions 2025 abstract13 Jun 2025

Myotube atrophy

downin human cells1

1 study

Icovamenib protects against myotube atrophy in human cells.
“Icovamenib protected against Activin A-induced myotube atrophy, displaying a pronounced increase in myotube width”
CellsActivin A-induced atrophymyotubes16 days
Icovamenib Rescues Human Myotube Atrophy Ex Vivo and Displays Complete Lean Mass Preservation in a Type 2 Diabetes Rat Model
ADA Scientific Sessions 2025 abstract13 Jun 2025

Myotube morphology

upin human cells1

1 study

Icovamenib increases myotube morphology in human cells.
“Icovamenib treatment resulted in a dose-dependent increase in healthy myotube length and width.”
Cellshealthy 3D-engineered myotubesmyotubes16 days
Icovamenib Rescues Human Myotube Atrophy Ex Vivo and Displays Complete Lean Mass Preservation in a Type 2 Diabetes Rat Model
ADA Scientific Sessions 2025 abstract13 Jun 2025